AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34377934
Drug: Adjuvant clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant clodronate (1600 mg daily for 3 years)
Trial: 32286643
Drug: Vaccine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (20 µg, n = 201)
Trial: 33045330
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (LB) 133 mg with 7.5 mL of 0.5% and 7.5 mL of 0.25% plain bupivacaine
Trial: 33045330
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine 25 mL of 0.5%
Trial: 33215755
Drug: Conventionally loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally loaded implants
Trial: 33270911
Drug: chronoIFLO5 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chronoIFLO5 (irinotecan 180 mg/sqm, oxaliplatin 80 mg/sqm, fluorouracil 2800 mg/sqm, leucovorin 1200 mg/sqm) administered every 3 weeks for 5 days
Trial: 32205276
Drug: 3-D printed
RxNorm normalized name: trans-resveratrol 3-β-D-glucoside
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-D printed porous titanium implants
Trial: 34388297
Drug: Tofogliflozin 20
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 20 mg/d
Trial: 35100917
Drug: HIPEC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC with cisplatin (60 mg/m2 administered on days 1 and 3, 30 mg/m2 each time) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Trial: 35100917
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with cisplatin (60 mg/m2 intravenously) plus oral S‐1 (40–60 mg, twice daily for 14 days)
Trial: 35346549
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg daily for 14 days
Trial: 32553717
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg/emtricitabine (FTC) 200 mg, 7 doses/week (perfect adherence)
Trial: 32553717
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg/emtricitabine (FTC) 200 mg, 4 doses/week (moderate adherence)
Trial: 32553717
Drug: TDF 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF 300 mg/emtricitabine (FTC) 200 mg, 2 doses/week (low adherence)
Trial: 35112974
Drug: sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib (400 mg/day)
Trial: 37206222
Drug: KCZ‐ILs (KCZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCZ‐ILs (KCZ, 4.72 mg/g)
Trial: 37206222
Drug: Daktarin® (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daktarin® (control group; KCZ, 20 mg/g)
Trial: 34289330
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus vouchers for attendance (VOU)
Trial: 34289330
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus text reminders (REM)
Trial: 34289330
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus vouchers and text reminders (VOU + REM)
Trial: 34289330
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (STD)
Trial: 32847776
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg (D30, N = 22)
Trial: 32847776
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg (D60, N = 22)
Trial: 32847776
Drug: Duloxetine 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 90 mg (D90, N = 22)
Trial: 33428233
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 40 ppm
Trial: 33796915
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and atezolizumab
Trial: 36141627
Drug: 2 servings/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 servings/day of nutritionally complete ONS powder (Fresubin® Powder), 600 kcal, 22.4 g protein for 12 weeks
Trial: 34193499
Drug: Preference-based smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference-based smoking cessation intervention (STOP) using various nicotine substitutes (patches, inhalers, gum, tablets, etc.) and/or electronic cigarettes delivered free of charge.
Trial: 34021843
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation with cisplatin (CCRT)
Trial: 32191600
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (0.06 g/kg/meal; n = 10)
Trial: 32191600
Drug: Alanine control
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alanine control (0.06 g/kg/meal; n = 10)
Trial: 36158131
Drug: TPVB (thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPVB (thoracic paravertebral block) with 15 mL of 0.375% ropivacaine hydrochloride
Trial: 32324592
Drug: immunotherapy (IT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunotherapy (IT) + anti-VEGFR (aVEGFR) + platinum-based therapy (Plat)
Trial: 32324592
Drug: immunotherapy (IT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunotherapy (IT) + aVEGFR + Plat
Trial: 32798360
Drug: Other oral
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other oral hypoglycaemic agents, insulin or statins
Trial: 34698901
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg single oral dose
Trial: 34698901
Drug: Lorlatinib 50
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lorlatinib 50 mg intravenous (IV) dose
Trial: 34698901
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and IV lorlatinib
Trial: 32635768
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment in black patients
Trial: 32635768
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment in nonblack patients
Trial: 32833109
Drug: N-acetylcysteine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine administration
Trial: 35608802
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (ST)
Trial: 35499850
Drug: 0.7 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/kg/d fenfluramine
Trial: 35499850
Drug: 0.2 mg/kg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/d fenfluramine
Trial: 33369488
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of preoperative antibiotics
Trial: 33369488
Drug: 2 days
RxNorm normalized name: Chapstick 12 Days of Christmas KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of preoperative antibiotics
Trial: 36223712
Drug: Personalized Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized Mg treatment (mean dose 205.58 mg/day, range 77.25 to 389.55 mg/day)
Trial: 36223712
Drug: Personalized Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized Mg treatment
Trial: 34941423
Drug: molnupiravir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molnupiravir (800 mg)
Trial: 34941423
Drug: molnupiravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: molnupiravir (400 or 800 mg)
Trial: 35050343
Drug: AI system
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI system for subtask 2 (treatment planning)
Trial: 37186577
Drug: Azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20 mg/kg)
Trial: 35308069
Drug: Chronic L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic L-arginine supplementation (5 g, twice a day for 13 days)
Trial: 35308069
Drug: Acute L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute L-arginine supplementation (5 g)
Trial: 35308069
Drug: Chronic placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic placebo supplementation (5.5 g dextrin, twice a day for 13 days)
Trial: 35308069
Drug: Acute placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute placebo supplementation (5.5 g dextrin)
Trial: 34864156
Drug: Empirical dietary/lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical dietary/lifestyle interventions and laxative therapy
Trial: 34864156
Drug: General treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General treatment options
Trial: 34076977
Drug: Cisplatin treatment
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin treatment (0 μM, 2 μM, 4 μM, 8 μM, 16 μM)
Trial: 33137100
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (MDA) with albendazole targeting eligible individuals of all ages (20 clusters)
Trial: 616777178
Drug: Intra-articular lumbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular lumbar facet joint corticosteroid injection
Trial: 34780683
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily
Trial: 32515067
Drug: Compassion-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassion-focused therapy (CFT) group intervention, 12 sessions, 2 hours each
Trial: 33378717
Drug: Bimanual or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimanual or unimanual intensive therapy
Trial: 34874418
Drug: YEARS rule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YEARS rule combined with age-adjusted D-dimer threshold (D-dimer <1000 ng/mL or <500 ng/mL for age <50 years or age in years × 10 for patients ≥50 years)
Trial: 32384509
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (co‐qingdai capsule, compound glycyrrhizin tablet, AA Skincare jojoba Oil)
Trial: 39536238
Drug: Tirzepatide 15
RxNorm normalized name: tirzepatide 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 15 mg
Trial: 39536238
Drug: Tirzepatide 5
RxNorm normalized name: tirzepatide 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 5 mg
Trial: 35634931
Drug: IAT (conventional-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAT (conventional-dose cytarabine, idarubicin, and thioguanine)
Trial: 35634931
Drug: IdAraC-Ida (intermediate-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IdAraC-Ida (intermediate-dose cytarabine and idarubicin)
Trial: 35624408
Drug: Eliapixant 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant 750 mg
Trial: 33986030
Drug: Eliapixant ≥50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant ≥50 mg
Trial: 33986030
Drug: Eliapixant (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliapixant (all doses)
Trial: 32394478
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) - 2000 shocks, frequency of 3 Hz, maximum total energy flow density 0.25 mJ/mm2, once a week for 4 weeks
Trial: 36383907
Drug: Antibody-drug conjugates
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibody-drug conjugates (ADCs)
Trial: 34839332
Drug: Off drug
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off drug (3-month follow-up)
Trial: 34631030
Drug: Methylnaltrexone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone (12 mg once daily or 12 mg once every other day; oral methylnaltrexone 150, 300, or 450 mg daily)
Trial: 35323856
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with TPC (paclitaxel, cisplatin, capecitabine)
Trial: 35323856
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with PF (cisplatin, fluorouracil)
Trial: 35323856
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with TPC
Trial: 32847735
Drug: Never tried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Never tried to lose at least 10 lbs, ate 0−2 servings of fruits and vegetables daily, or engaged in 0−29 min of physical activity weekly
Trial: 32527192
Drug: Intensified loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified loading strategy (ILS) with prasugrel 60 mg
Trial: 32527192
Drug: Standard loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard loading strategy with clopidogrel 600 mg
Trial: 37541951
Drug: Ketamine (subanaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (subanaesthetic doses)
Trial: 33906086
Drug: Abemaciclib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib (150 mg twice daily) + fulvestrant/NSAI
Trial: 33559090
Drug: AEA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEA group (antofloxacin 200 mg once daily, esomeprazole 20 mg + amoxicillin 1000 mg twice daily for 14 days)
Trial: 34628742
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and medication group 1 (2 Hz continuous wave)
Trial: 34628742
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and medication group 2 (50 Hz continuous wave)
Trial: 34628742
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and medication group 3 (2 Hz/50 Hz disperse-dense wave)
Trial: 34628742
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (conventional medication)
Trial: 35123290
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy (DBT)
Trial: 34414814
Drug: Joint mobilization
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint mobilization and therapeutic exercises (physical therapy group)
Trial: 33992570
Drug: CRT-P (Cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-P (Cardiac Resynchronization Therapy without Defibrillator)
Trial: 32896992
Drug: Single-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose regimen of methotrexate (MTX)
Trial: 32896992
Drug: Triple-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-dose regimen of methotrexate (MTX)
Trial: 33574371
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (8 oz daily)
Trial: 35144303
Drug: Femoral triangle
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral triangle block (FTB) and interspace between the popliteal artery and the capsule of the posterior knee (IPACK)
Trial: 35144303
Drug: Intra-articular cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular cocktail analgesic mixture local injection
Trial: 32990311
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy visits (number and timing)
Trial: 32675019
Drug: 52 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52 mL/day EVOO
Trial: 32675019
Drug: DieTBra +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DieTBra + 52 mL/day EVOO
Trial: 35780807
Drug: Odevixibat 40
RxNorm normalized name: ODEVIXIBAT 400MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odevixibat 40 μg/kg per day
Trial: 38670135
Drug: Odevixibat 120
RxNorm normalized name: ODEVIXIBAT 1200MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odevixibat 120 μg/kg per day
Trial: 35780807
Drug: Combined odevixibat
RxNorm normalized name: Odevixibat
DrugBank: Odevixibat (DB16261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combined odevixibat group (40 μg/kg and 120 μg/kg)
Trial: 32894637
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination therapy (metformin plus vildagliptin)
Trial: 35852694
Drug: Test cream
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test cream (steroid + synthetic pseudo‐ceramide), applied twice daily for 2 weeks
Trial: 35852694
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream (steroid without pseudo‐ceramide), applied twice daily for 2 weeks
Trial: 32467099
Drug: First-line platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line platinum-based chemotherapy
Trial: 36169608
Drug: Isotope phosphorus-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotope phosphorus-32 dressing combined with diprospan and mucopolysaccharide polysulphate cream
Trial: 36169608
Drug: Diprospan combined
RxNorm normalized name: Irospan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprospan combined with mucopolysaccharide polysulphate cream
Trial: 36169608
Drug: Isotopic phosphorus-32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotopic phosphorus-32 dressing combined with mucopolysaccharide polysulphate cream
Trial: 34521166
Drug: Bioabsorbable steroid-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioabsorbable steroid-eluting sinus stent in one frontal sinus ostium (FSO)
Trial: 35305325
Drug: E-cigarette product
RxNorm normalized name: vitamin E Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-cigarette product placement in music videos (treatment group)
Trial: 34350385
Drug: Volasertib (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (350 mg intravenous on days 1 and 15 in 4‐wk cycles) combined with low‐dose cytarabine (LDAC; 20 mg subcutaneous, twice daily, days 1‐10)
Trial: 34350385
Drug: Volasertib (V)
RxNorm normalized name: Penicillin V
DrugBank: Volasertib (DB12062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (V) plus low‐dose cytarabine (LDAC)
Trial: 36243199
Drug: Seasonal influenza
RxNorm normalized name: seasonal influenza, intradermal, preservative free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal influenza vaccine
Trial: 34166373
Drug: Single ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ultrasound-guided hyaluronic acid injection
Trial: 35646743
Drug: Fufang Furong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Furong Effervescent Suppository
Trial: 33106174
Drug: non-invasive cervical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-invasive cervical VNS (nVNS) for 5 days in addition to standard treatment
Trial: 33106174
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment alone
Trial: 37245250
Drug: No β-blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No β-blocker therapy
Trial: 32215899
Drug: Iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 400 mg/ml (group A)
Trial: 32215899
Drug: Iomeprol 300
RxNorm normalized name: Iomeprol 300 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 300 mg/ml (group B)
Trial: 35103366
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of tuberculin PPD
Trial: 35103366
Drug: Cryotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy plus intralesional injection of tuberculin PPD
Trial: 34477473
Drug: Prolonged-release Hydeal-D
RxNorm normalized name: loratadine / pseudoephedrine Extended Release Oral Tablet [Alavert D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release Hydeal-D 0.2% vaginal gel applied every three days for 12 weeks
Trial: 34477473
Drug: Prolonged-release Hydeal-D
RxNorm normalized name: loratadine / pseudoephedrine Extended Release Oral Tablet [Alavert D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release Hydeal-D 0.2% vaginal gel